Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to seek approval.